KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest ExpensesInterest ExpensesNet Income towards Common StockholdersNon Operating IncomeNon Operating Investment IncomeNon Operating Investment IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax RateTax Rate
Others
Accumulated Depreciation & AmortizationAccumulated Depreciation & AmortizationCost of RevenueEBIATGross ProfitLeasesLong-Term Debt RepaymentsOther Gross PP&E AdjustmentsOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Property, Plant & Equipment (Gross)Receivables - NetReceivables - OtherShares IssuedShares OutstandingShares OutstandingShares Repurchased
Ratios

Bio-Rad Laboratories (BIO) Shares Outstanding (2016 - 2026)

Bio-Rad Laboratories has reported Shares Outstanding over the past 17 years, most recently at $5.1 million for Q1 2026.

  • Quarterly Shares Outstanding fell 77.55% to $5.1 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $5.1 million through Mar 2026, down 77.55% year-over-year, with the annual reading at $5.1 million for FY2025, 79.89% down from the prior year.
  • Shares Outstanding was $5.1 million for Q1 2026 at Bio-Rad Laboratories, roughly flat from $5.1 million in the prior quarter.
  • Over five years, Shares Outstanding peaked at $25.2 million in Q4 2023 and troughed at $5.1 million in Q2 2022.
  • The 5-year median for Shares Outstanding is $5.1 million (2024), against an average of $12.8 million.
  • Year-over-year, Shares Outstanding skyrocketed 396.19% in 2022 and then crashed 79.89% in 2025.
  • A 5-year view of Shares Outstanding shows it stood at $5.1 million in 2022, then rose by 0.43% to $5.1 million in 2023, then skyrocketed by 394.34% to $25.2 million in 2024, then crashed by 79.89% to $5.1 million in 2025, then decreased by 0.0% to $5.1 million in 2026.
  • Per Business Quant, the three most recent readings for BIO's Shares Outstanding are $5.1 million (Q1 2026), $5.1 million (Q4 2025), and $21.9 million (Q3 2025).